NIH begins testing Ebola treatment in early-stage trial

(NIH/National Institute of Allergy and Infectious Diseases) A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the NIH Clinical Center in Bethesda, Md. The Phase 1 clinical trial is examining the safety and tolerability of a single monoclonal antibody called mAb114, which was developed by scientists at NIAID and their collaborators. Investigators aim to enroll between 18 and 30 healthy volunteers aged 18 to 60. The trial will not expose participants ...